All Articles by Author:

Bob

Endometrial Cancer PDX-Derived Organoids (PDXOs) and PDXs with FGFR2c Isoform Expression Are Sensitive to FGFR Inhibition

[npj Precision Oncology] Researchers reported the establishment of 16 endometrial cancer (EC) PDXOs with or without FGFR2c expression. In vitro treatment of five EC PDXOs with BGJ398 showed significant cell death in three models with FGFR2c expression.

Single-Cell Transcriptome Profiling of Primary Tumors and Paired Organoids of Pancreatobiliary Cancer

[Cancer Letters] The authors conducted scRNA-seq for paired primary tumors and organoids from one cholangiocarcinoma and two pancreatic ductal adenocarcinoma patients.

Proteome Signatures of Joint Toxicity to Arsenic (as) and Lead (Pb) in Human Brain Organoids with Optic Vesicles

[Environmental Research] Investigators utilized brain organoids with optic vesicles to systematically analyze the neurotoxicity of arsenic and lead.

Pathological Deficit of Cystatin B Impairs Synaptic Plasticity in EPM1 Human Cerebral Organoids

[Molecular Neurobiology] Scientists investigated the involvement of cystatin B in synaptic plasticity, using synaptosomes from human cerebral organoids as well as from rodents’ brain.

3D Hepatic Organoid Production from Human Pluripotent Stem Cells

[Differentiation] Researchers described the stepwise and fully 3D production of hepatic organoids from hPSCs. They optimized every differentiation step by screening for optimal concentrations and timing of differentiation signals in each differentiation step.

Bioprinting Using Organ Building Blocks: Spheroids, Organoids, and Assembloids

[Tissue Engineering Part A] Investigators discuss the expanding range of organ building blocks (OBB), presents the rapidly evolving collection of bioprinting and bioassembly methods using these OBB, and outlines the advantages, challenges, and future perspectives of employing OBB in organ printing.

Popular

Type 1 Diabetes Mellitus Prevention: Present and Future

[Nature Reviews Endocrinology] The authors explore current and potential therapeutics for T1DM prevention. They offer alternative approaches, such as targeting the receptor for advanced glycation end products.

Advancing Therapeutics in Small-Cell Lung Cancer

[Nature Cancer] Investigators highlight key advances in small cell lung cancer biology, therapeutic innovation, and biomarker development. Finally, they discuss the role of reverse translation in optimizing treatments, approaches to overcoming resistance, and ensuring equitable access to care.

The Next Generation of Immunotherapies for Lung Cancers

[Nature Reviews Clinical Oncology] Scientists provide an overview of emerging immunotherapies in clinical development for NSCLC and/or small cell lung cancer, including novel immune-checkpoint modulators, immune cell engagers, adoptive cell therapies, and therapeutic cancer vaccines.